Kenneth E Walsh

US Patent:

6369039, Apr 9, 2002

Filed:

Dec 3, 1998

Appl. No.:

09/204254

Inventors:

Maria Palasis - Wellesley MA
Kenneth Walsh - Carlisle MA

Assignee:

Scimed Life Sytems, Inc. - Maple Grove MN

International Classification:

A61K 4800

US Classification:

514 44, 514 2, 424 932, 604 51, 604 52, 604 53

Abstract:

A method of site-specifically delivering a therapeutic agent to a target location within a body cavity, vasculature or tissue. The method comprises the steps of providing a medical device having a substantially saturated solution of therapeutic agent associated therewith; introducing the medical device into the body cavity, vasculature or tissue; releasing a volume of the solution of therapeutic agent from the medical device at the target location at a pressure of from about 0 to about 5 atmospheres for a time of up to about 5 minutes; and withdrawing the medical device from the body cavity, vasculature or tissue. In another aspect, the present invention includes a system for delivering a therapeutic agent to a body cavity, vasculature or tissue, comprising a medical device having a substantially saturated solution of the therapeutic agent associated therewith.

US Patent:

RE37933, Dec 10, 2002

Filed:

Dec 21, 2000

Appl. No.:

09/740876

Inventors:

Didier Branellec - Brie-Comte-Robert, FR
Kenneth Walsh - Carlisle MA
Jeffrey M. Isner - Weston MA
Patrice Denefle - Saint Maur, FR

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

A61K 3576

US Classification:

424 932, 435456, 4353201, 435325, 435375, 514 44, 536 235

Abstract:

The present invention relates to replication defective recombinant viruses which contain at least one inserted gene encoding all or part of the protein GAX or of a variant of this protein, and to their therapeutic use, in particular for treating post-angioplastic restenosis.

US Patent:

6689807, Feb 10, 2004

Filed:

Jun 8, 2000

Appl. No.:

09/590740

Inventors:

Kenneth Walsh - Carlisle MA

Assignee:

Caritas St. Elizabeths Medical Center of Boston, Inc. - Boston MA

International Classification:

A01N 4336

US Classification:

514423, 514510, 435189

Abstract:

This invention relates to methods and compositions for the treatment of conditions associated with vascular insufficiency, and to methods and compositions for screening assays to select agents that are useful for this purpose. In particular the invention relates to HMG CoA reductase inhibitors and their use in promoting angiogenesis in vivo and in activating Akt in vascular endothelial cells in vitro and in vivo.

US Patent:

6897293, May 24, 2005

Filed:

Aug 27, 2001

Appl. No.:

09/940673

Inventors:

David H. Gorski - Cleveland OH, US
Kenneth Walsh - Concord MA, US

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

C07K001/00
C12P021/06
C12N015/12

US Classification:

530350, 435 691, 536 231, 536 235, 536 232, 530399, 530358

Abstract:

A novel growth arrest homeobox gene has been discovered and the nucleotide sequences have been determined in both the rat and the human. The expression of the novel homeobox gene inhibits vascular smooth muscle cell growth. The growth arrest homeobox gene hereinafter referred to as the “Gax gene” and its corresponding proteins are useful in the study of vascular smooth muscle cell proliferation and in the treatment of blood vessel diseases that result from excessive smooth muscle cell proliferation, particularly after balloon angioplasty.

US Patent:

RE39219, Aug 1, 2006

Filed:

Jan 5, 2001

Appl. No.:

09/755320

Inventors:

David H. Gorski - Monmouth Junction NJ, US
Kenneth Walsh - Carlisle MA, US

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

C12N 15/12
C12N 15/63
C12N 1/21
C12N 5/10

US Classification:

435 691, 435243, 4353201, 435325, 536 235

Abstract:

A novel growth arrest homeobox gene has been discovered and the nucleotide sequences have been determined in both the rat and the human. The expression of the novel homeobox gene inhibits vascular smooth muscle cell growth. The growth arrest homeobox gene hereinafter referred to as the “Gax gene” and its corresponding proteins are useful in the study of vascular smooth muscle cell proliferation and in the treatment of blood vessel diseases that result from excessive smooth muscle cell proliferation, particularly after balloon angioplasty.

US Patent:

7368420, May 6, 2008

Filed:

Sep 29, 1999

Appl. No.:

09/408905

Inventors:

Kenneth Walsh - Carlisle MA, US

Assignee:

Caritas St. Elizabeth's Medical Center of Boston, Inc. - Boston MA

International Classification:

A31K 31/713

US Classification:

514 2, 514 44

Abstract:

This invention relates to methods and compositions for the treatment of apoptotic cell-death. In particular the invention relates to Akt molecules and their use in inhibiting apoptotic cell-death in cardiomyocytes, skeletal myocytes and/or vascular endothelial cells. In view of these discoveries, Akt molecules can be used to inhibit apoptotic cell-death of any of the foregoing cells, and in particular, to treat conditions (e. g. , myocardial infarction) that result in increased apoptotic cell-death of cardiomyocytes, skeletal myocytes and/or vascular endothelial cells.

US Patent:

8329650, Dec 11, 2012

Filed:

Oct 20, 2008

Appl. No.:

12/682898

Inventors:

Kenneth Walsh - Carlisle MA, US
Yuichi Oshima - Brookline MA, US
Noriyuki Ouchi - Nagoya, JP

Assignee:

Trustees of Boston University - Boston MA

International Classification:

A61P 9/10
A61P 39/06
C07K 14/545

US Classification:

514 151, 514 19, 514 164, 514 212, 514824, 514866, 530350

Abstract:

Described herein are methods and compositions related to the discovery that the Follistatin-like 1 protein (Fstl-1) has metabolic and cardioprotective effects in vivo. Fstl-1 and portions and derivatives or variants thereof can be used to treat or prevent metabolic diseases or disorders and to treat or prevent cardiac damage caused by interrupted cardiac muscle blood supply.

US Patent:

20030114382, Jun 19, 2003

Filed:

Oct 23, 2002

Appl. No.:

10/278759

Inventors:

Kenneth Walsh - Carlisle MA, US

International Classification:

A61K048/00
A61K038/17
G01N033/53
C12Q001/48

US Classification:

514/012000, 514/044000, 435/015000, 435/007100

Abstract:

This invention relates to methods and compositions for modulating endothelial cell viability, endothelial cell migration, and angiogenesis. In particular the invention relates to GSK3 molecules, agents that modify the kinase activity of these molecules, and use of the foregoing in modulating the endothelial cell viability, endothelial cell migration, and angiogenesis.